188292-91-3

Upstream product

• 108-24-7 acetic anhydride 
• 188292-90-2 5-[tert-Butoxycarbonyl-(2,5-dihydroxy-benzyl)-amino]-2-hydroxy-benzoic acid 
• 125697-93-0 lavendustin C 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 188293-04-1 (2,5-Dihydroxy-benzyl)-(4-hydroxy-3-tetradecylcarbamoyl-phenyl)-carbamic acid tert-butyl ester 
• 188293-01-8 (2,5-Dihydroxy-benzyl)-(3-hexylcarbamoyl-4-hydroxy-phenyl)-carbamic acid tert-butyl ester 
• 188293-00-7 (2,5-Dihydroxy-benzyl)-(4-hydroxy-3-methylcarbamoyl-phenyl)-carbamic acid tert-butyl ester 
• 188292-93-5 Acetic acid 4-acetoxy-2-{[(4-acetoxy-3-methylcarbamoyl-phenyl)-tert-butoxycarbonyl-amino]-methyl}-phenyl ester 
• 188292-98-0 Acetic acid 4-acetoxy-2-{[(4-acetoxy-3-tetradecylcarbamoyl-phenyl)-tert-butoxycarbonyl-amino]-methyl}-phenyl ester 
• 188292-96-8 Acetic acid 4-acetoxy-2-{[(4-acetoxy-3-hexylcarbamoyl-phenyl)-tert-butoxycarbonyl-amino]-methyl}-phenyl ester 

Relevant academic research and scientific papers

Synthesis and biological activity of 5-[(2,5-dihydroxybenzyl)amino]salicylic acid analogs as inhibitors of EGF receptor-associated protein tyrosine kinase

The synthesis and biological activity of a series of 5-[(2,5-dihydroxybenzyl)amino]salicylic acid derivatives (3-6) as analogs of the active partial structure (2) of the potent EGF-R tyrosine kinase inhibitor lavendustin A (1) are described. Analogs with an electron-withdrawing group in place of the carboxyl group of 2 showed activity. The N-hexylsalicylamide analog 6b (IC50 = 0.9 μM) was about four times more potent than 2.